[0-7]

CHEMOPREVENTIVE EFFECTS OF ETHYL 3-(4'-GERANYLOXY-3-METHOXYPHENYL)-2-PROPENOATE AND FERULIC ACID ON MOUSE COLON CARCINOGENESIS

Beom Seok Han¹, Dong Whan Shin¹, Young Na Yum^{1,2}, Jeong Sik Cho¹, Ki Wha Yang¹, Nobuo Takasuka², Tetsuyuki Takahashi², Hiroyuki Tsuda²

¹ Division of General Toxicology, National Institute of Toxicological Research

Ethyl 3-(4'-geranyloxy-3-methoxyphenyl)-2-propenoate (EGMP) and ferulic acid (FA) have been shown to inhibit development of aberrant crypt foci (ACF) in the azoxymethane (AOM)-treated rat colon. In the present study, inhibitory effects of EGMP and FA on the post-initiation stage of AOM-induced colon carcinogenesis were studied in male ddY mice. The animals were given 6 s.c. injections of AOM (10mg/kg body weight) during a 5 week period and thereafter fed basal diet containing EGMP or FA at concentrations of 1.0% or 0.2% for 21 weeks and then sacrificed. Relative liver weights in the group fed 1.0% EGMP were significantly increased as compared to those in AOM alone group (P<0.05). Tumor multiplicity in the large intestine with 0.2% EGMP was significantly decreased (to 46.7% of control value, P<0.01). Hyperplasia and adenoma multiplicity of the large intestine were also decreased by 0.2% EGMP as compared to AOM alone group (45.5% and 44.4% of control values, P<0.05 and P<0.01, respectively). Although not significant, FA showed a tendency to inhibit tumor development in the large intestine. BrdU labeling indices in the surrounding and tumor epithelium of the large intestine with 0.2% EGMP were significantly decreased (73% and 71% of control value, P<0.05 and P<0.01, respectively). Apoptosis labeling indices in the surrounding and tumor epithelium of the large intestine with 1.0%, 0.2% EGMP and 1.0% FA were significantly increased (to 2.56, 3.94 and 2.78 fold of control value, P<0.01, P<0.001, and P<0.05). These findings suggest that EGMP has potential as a chemopreventive agent against colon tumor development.

keyword: Chemoprevention, EGMP, FA, mouse colon carcinogenesis

²Department of Experimental Pathology and Chemotherpy, National Cancer Center Research Institute